Calcium Acetate
Drugs For Treatment Of Hyperkalemia and Hyperphosphatemia
- Drug class
- Drugs For Treatment Of Hyperkalemia and Hyperphosphatemia
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 7
- FDA reports (12 mo)
- 235
Overview
Plain-language summary, compiled from the cited regulatory records
Calcium acetate is a medication classified as a drug for the treatment of hyperkalemia and hyperphosphatemia [1]. It functions as a phosphate binder [1].
This active ingredient is approved to reduce serum phosphorus levels in patients with end-stage renal disease (ESRD) [1]. It is available under several brand names [1].
In the past 12 months, there have been 235 adverse event reports associated with calcium acetate [2]. The most frequently reported adverse events include diarrhea, fatigue, off-label use, acute kidney injury, and dizziness [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | May 15, 2026 |
| US United States | FDA | 3 | February 24, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
Correction of hyperphosphataemia associated with chronic renal failure in patients undergoing dialysis.
How to take
USUnited States· FDA
3 products
Uses
1 INDICATIONS AND USAGE Calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease.
( 1 )
How to take
Drug interactions
Known interactions involving Calcium Acetate. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL183800003 · revised April 22, 2025
- [2]FDA DailyMed · 000c044a-12ef-44… · revised June 1, 2021 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.